EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins

Go Kobayashi, Tetsutaro Hayashi, Yohei Sekino iD, Kenichiro Ikeda, Hikaru Nakahara, Kohei Kobatake iD, Keisuke Goto iD, Daiki Taniyama, Kazuya Kuraoka, Shintaro Akabane, Hiroaki Niitsu, Takao Hinoi und 2 weitere

International Journal of Urology · 2025

DOI: 10.1111/iju.70146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Go Kobayashi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Pathology, Department of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima, Japan. Hauptthemen laut MEDLINE: DNA Mismatch Repair, Colorectal Neoplasms, Hereditary Nonpolyposis, Carcinoma, Transitional Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Lynch syndrome (LS) is an inherited cancer predisposition caused by germline mutations in DNA mismatch repair (MMR) genes. Upper tract urothelial carcinoma (UTUC) is the third most common cancer associated with LS. In this study, we examined MMR protein expression in UTUC using immunohistochemistry to clarify the clinicopathological characteristics and prognostic significance of LS‐associated UTUC.

Methods

We analyzed the expression of MLH1, MSH2, MSH6, and PMS2 by immunohistochemistry in 118 cases of UTUC treated with radical nephroureterectomy. MMR deficiency was defined as tumors exhibiting less than 5% MMR protein expression. We conducted further investigations using public databases.

Results

MMR deficiency was identified in 15 (13%) of the 118 UTUC cases. These cases were associated with younger age, papillary morphology, low grade, low stage, low neutrophil‐to‐lymphocyte ratio, high levels of CD8‐positive tumor‐infiltrating lymphocytes, and favorable prognosis. Similar findings were observed through in silico analysis. Public datasets revealed that tumor mutational burden in UTUC was significantly higher in MMR‐mutated cases compared to MMR‐normal cases. A waterfall plot showed a high frequency of FGFR3 mutation in MMR‐mutated cases in UTUC. Bioinformatics analysis using RNA‐Seq datasets showed that MMR‐mutated UTUC was associated with enriched gene sets for MYC targets v1 and oxidative phosphorylation. Furthermore, gene expression levels of GALNT12 and FRMD3 emerged as potential predictors of MMR mutation in UTUC.

Conclusions

These findings highlight the clinical value of evaluating MMR protein expression by immunohistochemistry, which could inform treatment strategies and surveillance protocols for UTUC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Mismatch RepairColorectal Neoplasms, Hereditary NonpolyposisCarcinoma, Transitional CellKidney NeoplasmsUreteral NeoplasmsHumansMaleFemaleMiddle AgedAgedImmunohistochemistryPrognosisMismatch Repair Endonuclease PMS2MutL Protein Homolog 1DNA-Binding ProteinsMutS Homolog 2 ProteinAdultNephroureterectomyAged, 80 and overUrotheliumBiomarkers, TumorLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

clinicopathological significanceimmunohistochemistrylynch syndromemismatch repairupper tract urothelial carcinoma

Substanzen

PMS2 protein, humanMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MLH1 protein, humanDNA-Binding ProteinsMutS Homolog 2 ProteinG-T mismatch-binding proteinMSH2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Molecular Pathology, Department of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima, Japan.
  • Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Diagnostic Pathology, Kure Medical Center and Chugoku Cancer Center, National Hospital Organization, Kure, Japan.
  • Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

ORCID-Profile: Yohei Sekino, Kohei Kobatake, Keisuke Goto, Nobuyuki Hinata

Förderung

  • Takeda Science Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Kobayashi, G., Hayashi, T., Sekino, Y., Ikeda, K., Nakahara, H., Kobatake, K., Goto, K., Taniyama, D., Kuraoka, K., Akabane, S., Niitsu, H., Hinoi, T., Sentani, K., & Hinata, N. (2025). Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins. International Journal of Urology. https://doi.org/10.1111/iju.70146

Vancouver

Kobayashi G, Hayashi T, Sekino Y, Ikeda K, Nakahara H, Kobatake K, et al. Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins. International Journal of Urology. 2025. doi:10.1111/iju.70146

BibTeX
@article{Kobayashi2025,
  author = {Kobayashi, Go and Hayashi, Tetsutaro and Sekino, Yohei and Ikeda, Kenichiro and Nakahara, Hikaru and Kobatake, Kohei and Goto, Keisuke and Taniyama, Daiki and Kuraoka, Kazuya and Akabane, Shintaro and Niitsu, Hiroaki and Hinoi, Takao and Sentani, Kazuhiro and Hinata, Nobuyuki},
  title = {Clinicopathological Characteristics of Upper Tract Urothelial Cancer With Loss of Immunohistochemical Expression of Mismatch Repair Proteins},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70146}
}
Kostenlos starten →